{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "IMMX", "name": "Immix Biopharma, Inc.", "url": "https://frontierpicks.com/dossiers/IMMX/", "json_url": "https://frontierpicks.com/dossiers/IMMX.json", "status": "WATCHLIST", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a5", "n": 5 }, "current_thesis": "Immix Biopharma’s NXC-201 story hinges on late-September data extending the reported 95% response rate across more patients. Confirmation requires that update by 2026-09-30 before a weekly close below $11.00; company language does not establish a firm 2026 application deadline.", "invalidation_trigger": "A weekly close below $11.00 ends the market case; secondary invalidation is an expanded-cohort CR rate below the 2026-05-21 reported 95%, a disclosed treatment-related death or clinical hold, or no clinical update by 2026-09-30.", "catalyst_date": "2026-09-14", "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "oncology-immunology" ], "tags": [], "sources": [], "notes": [ "Single-asset name: NXC-201 in relapsed/refractory AL amyloidosis carries essentially the whole equity story; there is no revenue line to cushion a clinical or regulatory setback.", "Pre-revenue clinical stage. Q2 2026 opex was $12.5M against $232.1M cash and short-term investments at 2026-06-30 (10-Q filed 2026-08-07).", "NEXICART-2 is single-arm, n=45 enrolled (March 2026); headline CR rates to date come from the first 20 evaluable patients, so denominators change between updates.", "shares outstanding were 71.5M at 2026-06-30. Prior follow-on history is relevant to any future raise.", "The 10-Q filed 2026-08-07 contains no NEXICART-2 readout date and no BLA-submission timing; the late-September window comes from company communications and third-party research." ], "body_markdown": "## Current Thesis\n\nImmix Biopharma’s NXC-201 thesis depends on the late-September clinical update extending its reported response rate across more patients before a weekly close below $11.00 breaks the market case. The company reported complete responses (CRs) in 95% of the first 20 evaluable patients on 2026-05-21. NXC-201 is a chimeric antigen receptor T-cell (CAR-T) therapy being studied in relapsed/refractory light-chain (AL) amyloidosis. [Company clinical update, 2026-05-21](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/ex99-1.htm).\n\nThe regulatory timing requires correction: the same May release linked the expected end-March 2027 follow-up dataset to a biologics license application (BLA) and potential launch. That statement does not establish a firm 2026 submission deadline. The September update remains a clinical catalyst, but a year-end application cannot be treated as settled guidance. [Company clinical update, 2026-05-21](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/ex99-1.htm).\n\nAs an inference, the narrative is maturing — the supplied adjusted close weakened to $12.14 on 2026-09-11 while the company’s homepage still led with its 2026-08-04 conference announcement when checked on 2026-09-13. A larger-cohort efficacy update accompanied by a weekly close above the supplied $14.47 high would overturn that assessment. [Company latest-news display](https://immixbio.com/).\n\n## Bull Case\n\n- **Responses persisted through reported follow-up.** The 2026-05-21 release reported no relapses among complete responders as of that update. This is evidence of observed persistence within the reported group; it does not establish durability across the full trial. [Company clinical update](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/ex99-1.htm).\n- **Enrollment is already complete.** Immix announced enrollment completion on 2026-03-30, and its May prospectus described a fully enrolled 45-patient study. Recruitment is therefore not the outstanding milestone for this cohort. [March enrollment announcement](https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/ex99-1.htm), [May offering prospectus](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024869/form424b5.htm).\n- **Cash supports continued development.** The quarterly report filed on 2026-08-07 reported $232.1 million in cash, equivalents and short-term investments at 2026-06-30, alongside a second-quarter net loss of $11.6 million. Those figures support a funded-development interpretation without establishing a specific cash-runway date. [Second-quarter Form 10-Q](https://www.sec.gov/Archives/edgar/data/1873835/000149315226036643/form10-q.htm).\n\n## Bear Case\n\n- **The sample limits extrapolation.** The 2026-05-21 response headline covered 20 evaluable patients. That sample is too small to support a claim that the expanded cohort will reproduce the same response rate; comparisons also require comparable follow-up. [Company clinical update](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024707/ex99-1.htm).\n- **Financing has expanded equity supply.** The company’s 2026-05-21 underwriting agreement specified 16,778,524 newly issued common shares at a public offering price of $8.94 per share. This documents historical issuance, not evidence of another financing now. [Offering Form 8-K](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024872/form8-k.htm).\n- **Momentum has weakened before data.** The supplied 2026-09-11 observations show a 43.7% three-month price increase alongside a 14-period relative strength index (RSI) of 34.3. The positive longer-window change does not establish that the recent decline has ended.\n\n## Setup & Price Structure\n\nThe supplied split/dividend-adjusted daily series closed at $12.14 on 2026-09-11, 16.1% below its $14.47 52-week high. The $11.00 threshold remains the research invalidation level published on 2026-09-03; the available bars do not establish it as a repeatedly tested support shelf. A weekly close below $11.00 ends the price-supported thesis.\n\nCrowding is unmeasured. The 2026-09-11 price context supplies neither a moving-average value nor volume, short-interest or investor-flow observations, so it cannot establish distance above a rising average or identify who participated in the decline. The concrete attention event is the institutional meeting schedule announced on 2026-08-04 for September; attendance is not evidence of subsequent demand. [Conference announcement](https://www.globenewswire.com/news-release/2026/08/04/3338423/0/en/immix-biopharma-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference.html).\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-09-30, estimated — NEXICART-2 update.** The May prospectus specifies late September, without an exact day. The assessment depends on the expanded evaluable denominator, response rate, follow-up and disclosed safety outcomes. [May offering prospectus](https://www.sec.gov/Archives/edgar/data/1873835/000149315226024869/form424b5.htm).\n\n## Elapsed catalysts\n\n- **2026-09-14 to 2026-09-16 — Institutional meetings.** Immix’s 2026-08-04 release confirms participation in the Morgan Stanley Global Healthcare Conference. The announcement schedules meetings; it does not promise a clinical release. [Company announcement](https://www.globenewswire.com/news-release/2026/08/04/3338423/0/en/immix-biopharma-to-participate-in-the-morgan-stanley-24th-annual-global-healthcare-conference.html). *(passed 4d ago)*\n\n## What Would Change Our Mind\n\nLoss of the published market threshold would end this setup: a weekly close below $11.00 invalidates it. Clinical confirmation is defined as an update by 2026-09-30 reporting at least the May 95% CR rate across more evaluable patients, without a disclosed treatment-related death or clinical hold. This is a research hurdle, not a regulatory efficacy requirement.\n\nA lower expanded-cohort response rate fails that specific headline thesis, although unequal follow-up would limit any clinical comparison. September ending without the promised update also breaks the event-window case. Low conviction reflects the small initial sample, the weakened 2026-09-11 momentum reading and the unresolved application schedule; it does not imply a measured probability of regulatory approval.\n\n## Correlation Notes\n\nThis is a single-company clinical setup. The supplied 2026-09-11 observations contain no paired sector-return history, so they support no measured correlation claim or attribution of the decline to a biotechnology group move. The company-specific September update remains the observable test; a sector rally alone would not satisfy the clinical confirmation condition.", "first_seen": "2026-08-23", "last_analyzed": "2026-09-13T11:19:45+00:00", "last_synthesized": "2026-09-13", "last_update_source": "watchlist_research", "license": "Content © FrontierPicks. Cite the canonical URL." }